Table 1.
Demographic characteristics of pooled ZOE-50/70 participants with pre-existing pIMDs (TVC)
| Characteristic | RZV (n = 983) | Placebo (n = 960) |
|---|---|---|
| Age at first dose, mean (s.d.), years | 68.8 (9.6) | 69.4 (9.5) |
| Age category, n (%) | ||
| 50–59 years | 230 (23.4) | 208 (21.7) |
| 60–69 years | 165 (16.8) | 156 (16.3) |
| 70–79 years | 450 (45.8) | 468 (48.7) |
| ≥80 years | 138 (14.0) | 128 (13.3) |
| Sex, n (%) | ||
| Female | 589 (59.9) | 584 (60.8) |
| Male | 394 (40.1) | 376 (39.2) |
| Geographic ancestry, n (%) | ||
| White – Caucasian/European | 830 (84.4) | 829 (86.4) |
| Asian – East Asian | 64 (6.5) | 50 (5.2) |
| Asian – Japanese | 30 (3.1) | 27 (2.8) |
| African/African American | 11 (1.1) | 7 (0.7) |
| White – Arabic/North African | 9 (0.9) | 6 (0.6) |
| Other | 39 (4.0) | 41 (4.3) |
n: number of participants included in each group; n (%): number (percentage) of participants in a category; pIMD: potential immune-mediated disease; Placebo: participants receiving placebo; RZV: participants receiving the adjuvanted recombinant zoster vaccine; TVC: total vaccinated cohort; ZOE-50/70: RZV efficacy studies in adults ≥50 and ≥70 years of age, respectively.